MAKING TRANSCAVAL ACCESS, SIMPLE, SAFE & EFFECTIVE
After more than a decade of clinical trials, transcatheter aortic valve replacement (TAVR) is now a treatment option for patients with severe symptomatic aortic stenosis. It's been sited that patients undergoing transfemoral (TF) TAVR experience better outcomes compared with those requiring alternate access (largely transapical/direct aortic access).
Transcaval access enables delivery of large-caliber devices to the aorta in patients ineligible for transfemoral arterial access. Inadequate femoral artery access causes more than 100,000 people to not address symptomatic aortic stenosis due to insufficient femoral arterial lumen sizes to undergo Transcatheter Aortic Valve Replacement (TAVR). Without treatment, the average survival is only 2-3 years.
The Transmural Transcaval Closure Device is the first purpose-built closure device for transcaval access in patients not eligible for traditional femoral artery access for TAVR. Transcaval access remains the only alternate access strategy that is completely femoral and not limited by diffuse iliac calcification, retains transfemoral ergonomics, does not increase operator radiation exposure, and is transferrable to other interventional procedures.